Together with two recent studies40,41, in which tumor angiogenesis was disrupted by SHP2 inhibitors, our results from a genetic mouse model strongly suggest the anti-angiogenic potency of SHP2 inhibitors in cancer therapies. The gene discussed is PTPN11; the disease is neoplasm.